Ramtin Agah Acquires 15,000 Shares of RenovoRx, Inc. (NASDAQ:RNXT) Stock

RenovoRx, Inc. (NASDAQ:RNXT) insider Ramtin Agah acquired 15,000 shares of the firm’s stock in a transaction dated Tuesday, April 15th. The shares were purchased at an average price of $0.90 per share, for a total transaction of $13,500.00. Following the completion of the transaction, the insider now directly owns 1,113,460 shares in the company, valued at approximately $1,002,114. This trade represents a 1.37 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.

Ramtin Agah also recently made the following trade(s):

• On Friday, April 11th, Ramtin Agah purchased 20,000 shares of RenovoRx stock. The stock was acquired at an average price of $0.80 per share, with a total value of $16,000.00.
• On Tuesday, April 8th, Ramtin Agah acquired 26,000 shares of RenovoRx stock. The stock was acquired at an average price of $0.84 per share, for a total transaction of $21,840.00.

RenovoRx Stock Performance

Shares of NASDAQ:RNXT opened at $1.02 on Friday. The firm has a market cap of $37.28 million, a price-to-earnings ratio of -1.79 and a beta of 1.12. The firm has a fifty day moving average price of $0.97 and a 200 day moving average price of $1.13. RenovoRx, Inc. has a fifty-two week low of $0.75 and a fifty-two week high of $1.69.

RenovoRx (NASDAQ:RNXT) last announced its quarterly earnings results on Monday, March 31st. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The business had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.17 million. As a group, research analysts predict that RenovoRx, Inc. will post -0.4 earnings per share for the current year.

Hedge Funds Weigh In On RenovoRx

Several institutional investors have recently added to or reduced their stakes in RNXT. Citadel Advisors LLC bought a new position in shares of RenovoRx during the 4th quarter valued at approximately $49,000. Renaissance Technologies LLC purchased a new stake in RenovoRx during the fourth quarter valued at $84,000. Finally, Geode Capital Management LLC lifted its position in RenovoRx by 61.9% during the third quarter. Geode Capital Management LLC now owns 232,937 shares of the company’s stock valued at $247,000 after purchasing an additional 89,018 shares during the last quarter. Hedge funds and other institutional investors own 3.10% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $3.00 target price on shares of RenovoRx in a research note on Friday, April 4th.

About RenovoRx

RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.